Partnering with Carrick Therapeutics
Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer and are optimized to a patient’s individual tumour through identification of predictive biomarkers.
What we’re seeking
We are actively seeking new partners with compounds that target the key pathways in cancer progression and adaptive resistance, so if you would like to explore partnering opportunities with us and understand how our team of leading experts could help advance your asset, please contact Dr. Elaine Sullivan, CEO.
Why partner with Carrick Therapeutics?
Carrick Therapeutics is founded on the highly-experienced team we have brought together, scientific, clinical and commercial, with a proven track record of identifying and developing commercially-successful innovative medicines.
Our team includes leading oncology researchers from institutions at Cambridge, London, Oxford and Edinburgh working in close collaboration with the world-renowned Cancer Research UK’s network of research centres.
We have also established an outsourced partnership business model that provides us with access to expertise across key areas including biomarkers, preclinical, manufacturing, clinical and patient stratification.
Carrick Therapeutics was launched on the back of a $95m funding round led by a group of healthcare investors, including ARCH Venture Partners & Woodford Investment Management, with outstanding records of success in accelerating the development of cutting-edge science into new therapies.